Time-trend of the incidence and mortality of esophageal cancer from 2010 to 2018 and its statistics in 2018 in Henan, China

Abstract

Background It is great of significance to figure the time-trend of esophageal cancer (EC) and its current status for effective prevention and control, especially in EC high risk areas. As one of world-renowned high-risk areas, the epidemiology of EC in Henan has not been recently updated. Therefore, we aimed to depict the status quo of EC and analyze its time-trend in Henan. Methods The EC data were extracted from the Henan Provincial Cancer registry database derived from the population based cancer registry system, which covered 30.51% of the whole population in Henan and were qualified according to national and international guidelines. The incidence and mortality of EC were estimated by area (rural/urban), gender, and age groups. The age-standardized rates (ASRs) were calculated according to the Segi’s population. Joinpoint regression was used to calculate annual percentage change (APC) and average annual percentage change (AAPC) to evaluate the time-trend of EC. Results As estimated, there were 29,913 new EC cases in Henan, 2018. The crude incidence and the age-standardized incidence rate by world standard population (ASIRW) was 27.43/10 5 and 19.96/10 5 , respectively. The incidence in males and rural was 1.83 and 1.51 times higher than that in females and urban areas, respectively. Meanwhile, it was estimated that 22,688 deaths occurred in 2018. The crude mortality and the age-standardized mortality rate by world standard population (ASMRW) were 20.80/10 5 and 14.47/10 5 , respectively. Similarly, males and rural areas had higher mortality compared with females and urban areas. The age-specific incidence and mortality of EC showed significant increasing after 60–64 years group. In general, the time-trend of incidence (APC: −8.9, P<0.001) and mortality (APC: −7.6, P<0.001) of EC showed a significant decreasing trend since 2014, and downward trend were also observed in rural areas for incidence (APC: −5.2, P<0.001) and mortality (APC: −3.9, P<0.001) from 2010 to 2018. Conclusions The EC incidence and mortality in Henan has exhibited a significant declining trend in past years. Nonetheless, the disease burden remains high, especially in males and rural areas. Therefore, the ongoing prevention and control strategies of EC should be maintained alongside the establishment of more effective strategies.

Revealing the oncogenic role of elevated GNL3L expression in esophageal squamous cell carcinoma: insights into the STAT3 pathway

“…Esophageal cancer ranks as the eighth most prevalent cancer worldwide and the sixth leading cause of cancer-related mortality ( 1 ). The incidence of esophageal squamous cell carcinoma (ESCC) exhibits notable regional disparity, and within China, ESCC is the most predominant subtype of esophageal cancer ( 2 ). Despite advancements in treatment modalities such as surgery, radiotherapy, and systemic therapy (i.e., chemotherapy and immunotherapy), ESCC is associated with high rates in incidence and mortality, and overall poor prognosis.…”

Disease burden and related risk factors of esophageal cancer in China and globally from 1990 to 2021, with forecast to 2035: An analysis and comparison

“…Currently, research on the epidemiology of EC in China has strong regional limitations. For example, Zhang et al 18 studied EC in Henan Province from 2010 to 2018, while Wang et al 19 evaluated the incidence and mortality trends of EC in Huai’an District, Huai’an City, Jiangsu Province from 1990 to 2016. Previous studies cannot fully describe the recent EC burden in China.…”

Prognostic value of pretreatment systemic immune-inflammation index in Chinese esophageal squamous cell carcinoma patients receiving radical radiotherapy: A meta-analysis

“…[3,4] A great proportion of esophageal squamous cell carcinoma (ESCC) patients lose the probability of curative resection due to the advanced stages at diagnosis or poor physical condition. [5][6][7] Despite of the advances in the immunotherapy and molecular-targeted therapy, definitive radiotherapy still remains an important treatment for these patients, especially for the elderly and economically poor patients. [8,9] However, it is difficult to accurately identify the prognostic of Chinese ESCC patients receiving radical radiotherapy because few studies focused on this group of patients.…”